08 10月 2018 by admin in UncategorizedComments Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic
02 10月 2018 by admin in UncategorizedComments Crescendo Biologics shortlisted for Private Financing Deal of the Year at 2018 Scrip Awards
24 9月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
24 9月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
20 9月 2018 by admin in UncategorizedComments Crescendo Biologics shortlisted for Lifestars Awards 2018
19 9月 2018 by admin in UncategorizedComments Crescendo Biologics shortlisted for Cambridge Independent Science and Technology Awards 2018
18 9月 2018 by admin in UncategorizedComments resTORbio Appoints Meredith Manning as Chief Commercial Officer
11 9月 2018 by admin in UncategorizedComments Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer
06 9月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces CNTX-4975 Data Presentation at PAINWeek 2018 National Conference
04 9月 2018 by admin in UncategorizedComments TEMPEST THERAPEUTICS NAMES DR. GINNA LAPORT CMO – Dr. Alicia Levey promoted to CBO –
15 8月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors
15 8月 2018 by admin in UncategorizedComments resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
14 8月 2018 by admin in UncategorizedComments Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda
07 8月 2018 by admin in UncategorizedComments Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
31 7月 2018 by admin in UncategorizedComments Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
30 7月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Financial Executive Nick Harvey as Chief Financial Officer
25 7月 2018 by admin in UncategorizedComments resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101
11 7月 2018 by admin in UncategorizedComments resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older
10 7月 2018 by admin in UncategorizedComments Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018
26 6月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Veteran Healthcare Innovator Joseph R. Swedish to its Board of Directors
21 6月 2018 by admin in UncategorizedComments Crescendo Biologics Appoints Clinical Development Expert, Dr Igor Matushansky, as Non-Executive Director
14 6月 2018 by admin in UncategorizedComments Syros Announces Appointment of Michael W. Bonney to Its Board of Directors
13 6月 2018 by admin in UncategorizedComments Crescendo Biologics Appoints Eva-Lotta Allan as Non-Executive Director
12 6月 2018 by admin in UncategorizedComments resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical Development
31 5月 2018 by admin in UncategorizedComments Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications
10 5月 2018 by admin in UncategorizedComments Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
09 5月 2018 by admin in UncategorizedComments resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly
30 4月 2018 by admin in UncategorizedComments Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing
29 3月 2018 by admin in UncategorizedComments resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
29 3月 2018 by admin in UncategorizedComments ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer
28 3月 2018 by admin in UncategorizedComments Tempest Therapeutics Closes $70 Million Series B Financing – Cancer immunology programs launched from Versant’s Inception Discovery Engine –
26 3月 2018 by admin in UncategorizedComments ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
19 3月 2018 by admin in UncategorizedComments resTORbio Announces Formation of Clinical Advisory Board
12 3月 2018 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
